JANX
Janux Therapeutics Inc

912
Loading...
Loading...
News
all
press releases
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...
Business Wire·9mo ago
News Placeholder
More News
News Placeholder
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...
Business Wire·9mo ago
News Placeholder
Janux Therapeutics Announces Proposed Public Offering
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...
Business Wire·9mo ago
News Placeholder
Janux Therapeutics Stock Hits 7-Month High On Prostate Cancer Drug Trial Data: Retail Confidence Spikes
The treatment, a tumor-activated T-cell engager, leverages the immune system by recruiting white blood cells to attack cancer cells.
Stocktwits·9mo ago
News Placeholder
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...
Business Wire·10mo ago
News Placeholder
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...
Business Wire·10mo ago
News Placeholder
Navigating 5 Analyst Ratings For Janux Therapeutics
Latest Ratings for JANX DateFirmActionFromTo Jul 2021B of A SecuritiesInitiates Coverage OnBuy Jul 2021Cowen & Co.Initiates Coverage OnOutperform Jul 2021HC Wainwright & Co.Initiates Coverage OnBuy...
Benzinga·1y ago
News Placeholder
Analyst Expectations For Janux Therapeutics's Future
Latest Ratings for JANX DateFirmActionFromTo Jul 2021B of A SecuritiesInitiates Coverage OnBuy Jul 2021Cowen & Co.Initiates Coverage OnOutperform Jul 2021HC Wainwright & Co.Initiates Coverage OnBuy...
Benzinga·1y ago
News Placeholder
Janux Therapeutics Announces Updates to Board of Directors
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...
Business Wire·1y ago
News Placeholder
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb PR Newswire VANCOUVER, BC, May 9, 2024 USA...
PR Newswire·1y ago

Latest JANX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.